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Abstract
Introduction: Cryopyrin-associated periodic syndrome is a rare genetic disorder causing cold-induced urticaria,
severe arthralgias, and (potentially) renal failure and hearing loss. Therapies that effectively control the symptoms
and prevent the complications of this debilitating disorder are now available, making recognition of this disease
important.
Case presentation: A 60-year-old Caucasian woman presented with complaints of rash and joint pains to a
general medicine clinic. Her history showed that her symptoms were linked to cold exposure, but the results of a
cold stimulation time test were negative. Several generations of her family had similar symptoms.
Conclusions: This case highlights the importance of considering cryopyrin-associated periodic syndrome in the
differential diagnosis of cold-induced urticaria. Several medications targeting interleukin-1-beta are available,
providing significant relief from symptoms and improvement in quality of life in affected patients.
Introduction
Cryopyrin-associated periodic syndrome (CAPS) is a
rare inherited inflammatory disorder with a unique
pathophysiology related to overproduction of interleu-
kin-1-beta (IL-1b). CAPS consists of three syndromes:
the familial cold autoinflammatory syndrome (FCAS),
Muckle-Wells syndrome (MWS), and neonatal onset
multisystem inflammatory disease (NOMID) (also
known as the chronic infantile neurologic, cutaneous,
articular [CINCA] syndrome). These disorders share a
number of phenotypic features and represent a conti-
nuum of disease severity; FCAS is at the milder end,
NOMID/CINCA syndrome is at the more severe end,
and MWS is an intermediate form. Although they are
described as distinct disorders, there is some overlap of
symptoms among them. Inflammasome overactivation
leading to overproduction of IL-1b underlies all of these
disorders, most often due to autosomal dominant
i n h e r i t a n c eo fm i s s e n s em u t a t i o n si nt h eg e n ec o d i n g
for cryopyrin [1].
Case presentation
A 60-year-old Caucasian woman presented to her pri-
mary care physician with complaints of chronic rash
and joint pains associated with exposure to cold. She
described episodes of fever and chills associated with an
erythematous maculopapular rash (Figure 1), headache,
and debilitating joint pains precipitated by cold. These
symptoms had been present since childhood and had
worsened over time. She reported that other family
members had experienced similar symptoms, reportedly
as far back as five generations. She had seen several
physicians for the evaluation of her symptoms, which
h a db e e na s c r i b e dt oav a r i e t yo fd i s o r d e r s ,i n c l u d i n g
s y s t e m i cl u p u se r y t h e m a t o s u sa n da c q u i r e dc o l du r t i -
caria. Her symptoms had been treated with steroids and
antihistamines, which provided little or no relief. A cold
stimulation time test was performed and did not pro-
duce an urticarial wheal. On the basis of her symptoms,
family history, and negative response to a cold time sti-
mulation test, a working diagnosis of CAPS was made.
This led to her enrollment in a clinical trial of an IL-1b
monoclonal antibody, providing near-complete relief
from her debilitating symptoms. Genetic testing later
confirmed a diagnosis of FCAS.
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The cold urticaria syndromes are a heterogeneous group
of disorders characterized by the development of inflam-
mation following cold exposure. Cold urticaria has a
variety of causes and can be classified broadly into
acquired and familial cold forms. Acquired cold urticaria
may occur as a primary disorder or secondary to
another process. Common secondary causes include
cryoglobulinemia, infectious diseases (syphilis, rubeola,
varicella, hepatitis, and infectious mononucleosis), or
certain drugs (penicillin, oral contraceptives, and angio-
tensin-converting enzyme inhibitors) [2]. The history of
response to cold exposure may give clues to whether a
cold-induced urticaria is an acquired cold urticaria or is
due to a familial cause. In contrast to the majority of
acquired cold urticarias, CAPS is characterized by a
delayed response to cold exposure. An early age of
onset as well as the presence of fever and symptoms
due to complications of CAPS may also help differenti-
ate it from acquired cold urticarias [2].
A key diagnostic test in the evaluation of cold-induced
urticaria is the cold stimulation time test. In this study,
a cold stimulus, such as an ice cube in a plastic bag, is
applied for five minutes
to the patient’s skin, which then is allowed to rewarm.
The test is considered positive if a coalescent wheal
forms. It then can be repeated with shorter times of
cold stimulation to better define the degree of sensitiv-
ity. If the test is negative with a five minute application,
it may be repeated with a 10-minute application [2,3].
The cold stimulation time test does not typically form
an urticaria wheal in patients with CAPS as its symp-
toms, unlike those of acquired cold urticaria, are not
mediated by histamine release.
CAPS is a systemic inflammatory disorder occurring
as a result of autosomal dominant or de novo mutations
in the gene NLRP3 (CIAS1). Mutations in this gene lead
to production of an altered form of the protein, cryo-
pyrin. Cryopyrin, as a member of the NALP3 inflamma-
some, activates caspase-1, which in turn activates IL-1b.
These changes are thought to cause a gain-of-function
effect of the NALP3 inflammasome, leading to overpro-
duction of IL-1b [4].
Inflammasome activation and IL-1b overproduction
have been implicated in the pathogenesis of a number
of diseases, including type 2 diabetes, gout, and rheuma-
toid arthritis [5]. A recent trial of IL-1b blockade in
people with type 2 diabetes showed improvements in
Figure 1 Rash in cryopyrin-associated periodic syndrome (CAPS). The rash seen in CAPS has an urticaria-like appearance. Our patient
brought this photograph with her to her first appointment with us.
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additional studies to better define the potential role of
IL-1b blockade in the treatment of diabetes are ongoing.
CAPS is a systemic inflammatory disorder affecting a
number of organ systems. Most commonly involved is
the skin, and a maculopapular, urticaria-like, and usually
nonpruritic rash is typical. Skin lesions are seen in the
first six months of life in nearly all patients [7] and at
birth in nearly two thirds of patients with CINCA/
NOMID [8]. The onset of symptoms following cold
exposure is delayed an average of two and a half hours
and duration is up to 12 hours in patients with FCAS,
and attacks in MWS last about one to two days [7,9].
The correlation of symptoms with cold exposure is less
consistent in MWS than in FCAS. CAPS may also affect
the musculoskeletal, renal, neurologic, and ocular sys-
tems. Joint symptoms range from arthralgias in FCAS to
severe joint deformation in CINCA/NOMID. Renal
involvement is often seen in patients with MWS and
CINCA/NOMID, and elevations in serum amyloid A
levels potentially lead to renal amyloidosis in about 25%
of patients with MWS [9]. Ocular involvement consists
mainly of conjunctivitis and episcleritis, although blind-
ness may occur in patients with CINCA/NOMID. Pro-
gressive sensorineural hearing loss is seen in about 60%
of patients with MWS [9].
Advances in the understanding of the pathogenesis of
CAPS resulted in the use of therapies targeting IL-1b in
the treatment of this disorder. First developed among
these agents was anakinra, a recombinant human IL-1
receptor antagonist. Originally approved for use in rheu-
matoid arthritis, it reduces the inflammation associated
with CAPS [10,11]. Anakinra has been shown to
improve symptoms of CAPS and also may reverse or
stabilize hearing loss and renal amyloidosis due to
CAPS [12]. The symptomatic improvements seen with
anakinra, however, are contingent upon continued daily
administration, and withdrawal leads to a re-emergence
of symptoms [10,11].
Rilonacept, a fusion protein of the extracellular IL-1
receptor and the Fc portion of human IgG1, is a newer
alternative therapy. This agent traps IL-1, binding it and
preventing it from interacting with the IL-1 receptor. Its
high affinity for IL-1b allows once-weekly dosing [13].
The safety and efficacy of rilonacept were evaluated in
two randomized, placebo-controlled trials, in which rila-
nocept therapy resulted in rapid and sustained improve-
ment of symptoms. Serum amyloid A and C-reactive
protein levels also were reduced with rilonacept. The
most common adverse events seen with rilonacept ther-
apy are injection site reactions and upper respiratory
infections [14].
Canakinumab is the newest medication released for
the treatment of CAPS. This agent is a fully human
anti-IL-1b monoclonal antibody with a plasma half-life
of 28 to 30 days, allowing dosing once every eight
weeks. In a randomized, double-blind, placebo-con-
trolled trial, canakinumab administration led to rapid
and sustained reduction of inflammatory symptoms and
normalization of serum amyloid A levels in patients
with CAPS. Canakinumab was well tolerated and caused
few injection site reactions, although the incidence of
suspected infection was higher versus placebo [15].
Conclusions
CAPS should be considered in the differential diagnosis
of any patient presenting with cold-induced urticaria-
like symptoms. As in our case, symptoms due to CAPS
may be attributed erroneouslyt oav a r i e t yo fd i s o r d e r s ,
such as acquired cold urticaria or other rheumatologic
disorders like systemic lupus erythematosus. A thorough
history, focusing on the timing of symptom onset in
relation to cold exposure and the presence of the other
family members with similar symptoms, helps identify
affected individuals. Several medications targeting IL-1b
are available, providing significant relief from symptoms
and improvement in quality of life in patients with
CAPS.
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